You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《汇丰轮证》石药掉头急挫 两手准备可留意牛68687/熊69272
阿思达克 11-29 10:50

美股假期休市,欧洲股市表现偏软,港股亦迎来较大调整,恒指裂口回挫188点开市,之後跌幅扩大,领头向下包括医药、港交所及个别手机股。石药(01093)及中药(01177)包办跌幅榜前列,其中石药开市急挫7%,一度跌穿18元水平,中药跌2%,暂时守住10元大关。国家卫健委官员表现,全面深化药品集中采购和使用改革,优化集中采购模式,有序扩大药品品种范围。市场担心药品格将有影响,拖累股价急挫跌幅进一步扩大,石药裂口跌破50天线,短期可留意两手准备的部署,博即市反弹可留意贴价新上市牛证68687, 收回价17.18元, 2020年6月到期 ,实际杠杆8.5倍。相反追沽的话,看淡可留意熊证69272,收回价 22.68, 2020年4月到期 ,实际杠杆3.5倍。多产品详情上www.warrants.hsbc.com.hk 查询。陈恩因

汇丰环球资本市场机构客户及财富管理联席总监

更新日期及时间: 2019年11月29日上午10:00

本结构性产品并无抵押品,如发行人无力偿债或违约,投资者可能无法收回部份或全部应收款项。

本文由香港上海汇丰银行有限公司(「本行」或「发行商」)发行(包括任何参考条款),仅供参考之用,并不构成邀约、游说、或建议出售或购买结构性产品。

结构性产品属复杂产品,投资者务须就此审慎行事,除非投资者完全了解及愿意承担所涉风险,否则切勿投资此产品。结构性产品价格可急升可急跌,投资者或会损失所有或大部分投资。过往表现并不反映将来表现。投资前应了解结构性产品之性质及风险,并详阅有关上市文件,独立决定是否适合自己,若需要应谘询专业建议。本行及其委任之流通量提供者可能是结构性产品的唯一市场参与者,而结构性产品的二级市场可能有限。谨请注意,牛熊证设有强制收回机制,因此有可能提早终止,在此情况下(i)N类牛熊证投资者会损失於牛熊证的全部投资;而(ii)R类牛熊证之剩余价值则可能为零。界内证在市场是全新的结构性产品,现时在香港交易所并无类似上市产品可作比较。界内证具备有别於标准的特徵,其条款及定价或较其他标准权证复杂,其最大潜在回报为固定及设有上限。界内证价格变动可能与其挂钩资产的价格变动不成比例或呈相反方向。

作者为金管局及证监会持牌人士,并无就结构性产品或相关资产持有任何直接或间接权益。~重要声明:

以上资讯由第三方提供,AASTOCKS.com Limited对於任何包含於、经由、连结、下载或从任何与本网站有关服务所获得之资讯、内容或广告,不声明或保证其内容之正确性或可靠性。对於您透过本网站上之广告、资讯或要约而展示、购买或取得之任何产品、资讯资料,本公司亦不负品质保证之责任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account